Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

ent. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials.

Participants in the MERLIN TIMI-36 study received modern therapy, with approximately 96 percent of patients on aspirin, approximately 89 percent on beta blockers and approximately 82 percent on statins. Approximately 59 percent of study participants received coronary angiography during their initial hospitalization.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to clinical trials and regulatory filings, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Md., Dec. 11 EntreMed, Inc. (Nasdaq: ... $1.7 million in royalty revenue from sales of ... royalty revenue of $3.3 million. In addition, ... and projected revenue for fiscal 2009. The ... third quarter will be reflected in the fourth ...
(Date:12/11/2009)... Biosciences Corporation announced today the enrollment and dosing at ... of the first patient in the ACE ( ... Phase 2 pivotal trial in patients with relapsed or ... novel, orally available, potent and highly selective small molecule ... (FLT3) inhibitor. The ACE study is designed to ...
(Date:12/11/2009)... 2009 -- Esco announces the opening of a NEW 2nd North ... technical service, training and logistics center to support Esco,s growth in ... Introductions (NPI) for temperature-controlled laboratory equipment. , ... Hatboro, ... a NEW 2nd North American facility in Marietta, OH. The facility ...
(Date:12/10/2009)... -- With the economy and markets exhibiting continued signs ... small cap equity research provider, will seek to educate ... the micro cap market at the firm,s First ... at the Grand Hyatt Hotel in New York, NY. ... undervalued by much of Wall Street, but the well-informed ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2
... Ben Holmes Named PartnerLONDON, March 3 Index ... early stage fund, Index Ventures V. The fund is ... biotechnology and clean technology sectors across Europe, the United States ... Index has raised in the past ten years and reinforces ...
... 2009 Just as sonar sends out sound waves ... can be used by scanning tunnelling microscopes to investigate ... As researchers from Gttingen, Halle and Jlich now report ... in making bulk Fermi surfaces visible in this manner. ...
... Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp ... multiple sclerosis (MS), announced that effective on March 16, ... each of which entitles the holder to purchase one ... per share, will be extended from March 23, 2009 ...
Other Biology Technology:Index Ventures Closes Euro 350 Million Early Stage Fund 2Latest issue of Science: Nanosonar uses electrons to measure under the surface 2BioMS Medical warrant extension 2
(Date:12/11/2009)... of the 4th edition of Springer,s classic reference and ... the Victor A. McKusick Leadership Award. The prize, which ... human genetics, was presented to him at the 59th ... on 24 October 2009 in Honolulu, Hawaii. , Motulsky ... the University of Washington in Seattle. One of the ...
(Date:12/11/2009)... weight by eating less and exercising more improved their ... of Medicine in St. Louis. , The results of ... issue of the Journal of the American College ... improvement in four key measures of heart and vascular ... decreased thickness of heart muscle, improved pumping and relaxation ...
(Date:12/11/2009)... the best dietary source of Omega 3, according to a ... (UAL). The scientists analysed the eggs, or roe, of 15 ... of these fatty acids, which are essential to the human ... of the nutritional potential of the roe of marine animals, ... shown that this is one of the best natural sources ...
Breaking Biology News(10 mins):Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3Roe of marine animals is best natural source of omega-3 2Celebrity Permanent Makeup Artist Slams Claim 26quot 3BMichael Jackson Didn 26apos 3Bt Want to be Black 26quot 3B 50958 1Celebrity Permanent Makeup Artist Slams Claim 26quot 3BMichael Jackson Didn 26apos 3Bt Want to be Black 26quot 3B 50958 2Celebrity Permanent Makeup Artist Slams Claim 26quot 3BMichael Jackson Didn 26apos 3Bt Want to be Black 26quot 3B 50958 3Enerkem Announces World Class Advanced Energy Research Center in Edmonton Alberta Canada 12924 1Enerkem Announces World Class Advanced Energy Research Center in Edmonton Alberta Canada 12924 2Enerkem Announces World Class Advanced Energy Research Center in Edmonton Alberta Canada 12924 3NIH Stem Cell Guidelines Ethically Irresponsible Scientifically Unworthy Useless to Patients Says Family Research Council 50952 1NIH Stem Cell Guidelines Ethically Irresponsible Scientifically Unworthy Useless to Patients Says Family Research Council 50952 2
... everything of importance in biology. The genome rules all of ... that among the diverse forms of RNA, a kind of ... and with genes directly to manage the genome from behind ... the vast stretches of DNA that do not code for ...
... time, researchers have inhibited the development of epilepsy after a ... signaling pathways in the brain, neurology researchers found that they ... , "We have shown that there is a window ... that epilepsy will develop," said one of the lead researchers, ...
... by consumers for healthier and more ecological foods has driven ... useful life of the products and that are, at the ... mixture of synthetic chemical compounds that are not completely biodegradable. ... years is the edible coating ?a transparent film that covers ...
Other Biology News:Peering into the shadow world of RNA 2Peering into the shadow world of RNA 3Gene therapy inhibits epilepsy in animals 2Edible coatings will be the packaging of the future 2Edible coatings will be the packaging of the future 3Edible coatings will be the packaging of the future 4
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
HSV-2 gD (0191)...
... ml Dynabeads Epoxy (4.5 m). Hydrophobic ... groups. Ideal for coupling of antibodies for ... initial coupling with covalent binding of primary ... groups (SH)) occurring within 16-20 hours. Coupling ...
Biology Products: